Background Image
Previous Page  133 / 156 Next Page
Information
Show Menu
Previous Page 133 / 156 Next Page
Page Background

131

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

85

Fainsinger RL, Nekolaichuk C, Lawlor P, Hagen N, Bercovitch M, Fisch M, Galloway L, Kaye

G, Landman W, Spruyt O, Zhukovsky D, Bruera E, Hanson J. An international multicentre

validation study of a pain classification system for cancer patients. Eur J Cancer 2010;

46(16): 2896-2904.

86

Fan BF. Postmarketing surveillance study of OxyContin tablets for relieving moderate to

severe postherpetic neuralgia pain. Oncology 2008; 74 Suppl 1: 66-71.

87

Farrar JT, Polomano RC, Berlin JA, Strom BL. A comparison of change in the 0-10 numeric

rating scale to a pain relief scale and global medication performance scale in a short-term

clinical trial of breakthrough pain intensity. Anesthesiology 2010; 112(6): 1464-1472.

88

Fassoulaki A, Melemeni A, Paraskeva A, Siafaka I, Sarantopoulos C. Postoperative pain

and analgesic requirements after anesthesia with sevoflurane, desflurane or propofol.

Anesth Analg 2008; 107(5): 1715-1719.

89

Feng X, Lin SQ, Chen Y, Wu XJ. [Effect of postoperative analgesia with flurbiprofen axetil

and sufentanyl on metabolism of surgical patients with intestinal carcinoma]. Nan Fang Yi

Ke Da Xue Xue Bao 2007; 27(10): 1567-1569.

90

Feng Y, Ju H, Yang B, An H. Effects of a selective cyclooxygenase-2 inhibitor on postope-

rative inflammatory reaction and pain after total knee replacement. J Pain 2008; 9(1):

45-52.

91

Ferguson SE, Malhotra T, Seshan VE, Levine DA, Sonoda Y, Chi DS, Barakat RR, Abu-Rust-

um NR. A prospective randomized trial comparing patient-controlled epidural analgesia

to patient-controlled intravenous analgesia on postoperative pain control and recovery

after major open gynecologic cancer surgery. Gynecol Oncol 2009; 114(1): 111-116.

92

Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability of fentanyl buccal

tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic

pain: an 18-month study. J Pain Symptom Manage 2010; 40(5): 747-760.

93

Fink DJ, Wechuck J, Mata M, Glorioso JC, Goss J, Krisky D, Wolfe D... Gene therapy for

pain: results of a phase I clinical trial. Ann Neurol 2011; 70(2): 207-212.

94

Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal

fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol

Ther 2010; 48(2): 138-145.

95

Fisher A, Watling M, Smith A, Knight A. Pharmacokinetics and relative bioavailability of

fentanyl pectin nasal spray. Int J Clin Pharmacol Ther 2010; 48(12): 860-867.

96

Fizazi K. Oral presentation at 46th ASCO meeting 2010. Chicago IL; 6.6.2012; Abstract

LBA4507.

97

Forastiere E, Sofra M, Giannarelli D, Fabrizi L, Simone G. Effectiveness of continuous

wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain

management after open nephrectomy. Br J Anaesth 2008; 101(6): 841-847.

98

FORBES K. Opioids in Cancer pain. Oxford, New York, Oxford University Press 2007;

99

Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose

morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract

2007; 7(2): 123-129.

Literaturverzeichnis